The 4Kscore Test as a Predictor of High-Grade Prostate Cancer

Video

Raoul S. Concepcion, MD, FACS, Urology Associates P.C., discusses the potential for the 4Kscore test as a predictor of high-grade prostate cancer.

Clinical Pearls

Raoul S. Concepcion, MD, FACS, Urology Associates P.C., discusses the potential for the 4Kscore test as a predictor of high-grade prostate cancer.

  • There remains a need for a way for physicians to determine which prostate cancer patients need to be biopsied and if the detected tumor is high-grade.
  • An early study of about 1000 patients analyzed the 4Kscore test in this space.
  • The 4Kscore test, with certain limits, may be able to predict higher-grade cancers. This test could reduce the number of biopsies without missing a significant number of high-grade tumors.
Recent Videos
Related Content
Lenvatinib, Pembrolizumab, and TACE Demonstrate Significant Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma

Lenvatinib, Pembrolizumab, and TACE Demonstrate Significant Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma

Ashley Chan
September 15th 2024
Article

A combination of lenvatinib, pembrolizumab, and TACE significantly improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma compared to dual placebo and TACE.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

Radium-223 Enhances Outcomes with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Radium-223 Enhances Outcomes with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Megan Hollasch
September 15th 2024
Article

Adding radium-223 to enzalutamide significantly improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases.

Read More

LaPelusa’s Journey in the Dynamic Field of GI Oncology

LaPelusa’s Journey in the Dynamic Field of GI Oncology

Jordyn Sava;Michael LaPelusa, MD
May 1st 2024
Podcast

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Listen

T-DXd Combinations Effective in HER2+ Gastric and GEJ Cancer

T-DXd Combinations Effective in HER2+ Gastric and GEJ Cancer

Sabrina Serani
September 14th 2024
Article

Findings from the DESTINY-Gastric03 study support the further exploration of the antibody-drug conjugate trastuzumab deruxtecan for the first-line treatment of patients with advanced HER2+ gastric, esophageal, and GEJ cancers.

Read More

Less Toxic, More Personalized Treatments on the Horizon in HER2+ Breast Cancer

Less Toxic, More Personalized Treatments on the Horizon in HER2+ Breast Cancer

Jordyn Sava
September 12th 2024
Article

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.

Read More